| Biochemical Relapse-Free Survival in Postprostatectomy Patients Receiving 18F-Fluciclovine-Guided Prostate Bed-Only Radiation: Post Hoc Analysis of a Prospective Randomized Trial.Pract Radiat Oncol | PMID 39032598PMC12447804 | 2024 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Early health technology assessment of gene silencing therapies for lowering lipoprotein(a) in the secondary prevention of coronary heart disease.J Clin Lipidol | PMID 39322524无 PMCID | 2024 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety, immunogenicity and immune-persistence of a lyophilized human rabies vaccine (Vero cells) under Zagreb and Essen regimens: a randomized, open-label, controlled phase III clinical trial in healthy participants aged 10-60 years in China.Front Immunol | PMID 39575262PMC11578971 | 2024 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Immunogenicity of dupilumab in adult and pediatric patients with atopic dermatitis.Front Immunol | PMID 39588375PMC11586717 | 2024 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Changes to inflammatory markers during 5 years of viral suppression and during viral blips in people with HIV initiating different integrase inhibitor based regimens.Front Immunol | PMID 39600696PMC11590120 | 2024 | 0.95 | The record is a Phase III randomized trial in humans with a drug intervention (antiretroviral therapy), but it is non-oncology (focused on HIV infections and inflammation markers, not malignant neoplasms). The primary endpoint is changes in inflammatory biomarkers, not a time-to-event efficacy outcome like OS or PFS. | 待处理 |
| Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies for Patients with COPD and Phenotypic Features of Asthma: A Pooled Post Hoc Analysis of KRONOS and ETHOS.Int J Chron Obstruct Pulmon Dis | PMID 39691156PMC11649577 | 2024 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Antidrug antibodies to adalimumab do not associate with immunologically related adverse events.Front Immunol | PMID 40084239PMC11904412 | 2024 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered as a booster to adults aged ≥59 years: A phase III randomized study.Hum Vaccin Immunother | PMID 36632042PMC9980625 | 2023-Dec-31 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Immunogenicity and safety of Biological E's CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial.Hum Vaccin Immunother | PMID 37113012PMC10294721 | 2023-Dec-31 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A randomized, observer-blind, controlled phase III clinical trial assessing safety and immunological non-inferiority of Vi-diphtheria toxoid versus Vi-tetanus toxoid typhoid conjugate vaccine in healthy volunteers in eastern Nepal.Hum Vaccin Immunother | PMID 37128723PMC10142305 | 2023-Dec-31 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and immunogenicity of rabies vaccine (PVRV-WIBP) in healthy Chinese aged 10-50 years old: Randomized, blinded, parallel controlled phase III clinical study.Hum Vaccin Immunother | PMID 37249318PMC10294720 | 2023-Dec-31 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase III study of bilayer sustained-release tramadol tablets in patients with cancer pain: a double-blind parallel-group, non-inferiority study with immediate-release tramadol capsules as an active comparator.Support Care Cancer | PMID 38157081PMC10756890 | 2023-Dec-29 | 0.95 | The study is a randomized, Phase III oncology trial with a drug intervention and original results, but it does not have a primary or key secondary time-to-event efficacy endpoint as required for inclusion. | 待处理 |
| Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.N Engl J Med | PMID 37921461无 PMCID | 2023-Dec-28 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Restrictive or Liberal Transfusion Strategy in Myocardial Infarction and Anemia.N Engl J Med | PMID 37952133PMC10837004 | 2023-Dec-28 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of nemolizumab in paediatric patients aged 6-12 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study.Br J Dermatol | PMID 37522351无 PMCID | 2023-Dec-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization.J Clin Oncol | PMID 37722087无 PMCID | 2023-Dec-20 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Biosimilar SB15 versus reference aflibercept in neovascular age-related macular degeneration: 1-year and switching results of a phase 3 clinical trial.BMJ Open Ophthalmol | PMID 38114333PMC10749085 | 2023-Dec-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial.Lancet | PMID 37931632无 PMCID | 2023-Dec-16 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA.Lancet | PMID 37979595无 PMCID | 2023-Dec-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efbemalenograstim alfa, an Fc fusion protein, long-acting granulocyte-colony stimulating factor for reducing the risk of febrile neutropenia following chemotherapy: results of a phase III trial.Support Care Cancer | PMID 38103088PMC10725375 | 2023-Dec-16 | 0.95 | The study meets criteria for oncology, human, randomized, Phase III, drug intervention, and original result. However, it fails the time-to-event criterion because the primary endpoint is duration of severe neutropenia (a continuous/mean difference endpoint), not a time-to-event efficacy endpoint (e.g., OS, PFS) requiring Kaplan-Meier analysis. | 待处理 |
| Early Video-assisted Thoracoscopic Surgery or Intrapleural Enzyme Therapy in Pleural Infection: A Feasibility Randomized Controlled Trial. The Third Multicenter Intrapleural Sepsis Trial-MIST-3.Am J Respir Crit Care Med | PMID 37820359PMC10765402 | 2023-Dec-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial.Clin Cancer Res | PMID 37843857无 PMCID | 2023-Dec-15 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Phase III randomized clinical studies to evaluate the immunogenicity, lot-to-lot consistency, and safety of ROTAVAC® liquid formulations (ROTAVAC 5C & 5D) and non-inferiority comparisons with licensed ROTAVAC® (frozen formulation) in healthy infants.Hum Vaccin Immunother | PMID 37968237PMC10760372 | 2023-Dec-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of eptinezumab in patients with chronic migraine and medication-overuse headache: a randomized, double-blind, placebo-controlled study.BMC Neurol | PMID 38102535PMC10722704 | 2023-Dec-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.N Engl J Med | PMID 37870955PMC11188986 | 2023-Dec-14 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults.N Engl J Med | PMID 38091530无 PMCID | 2023-Dec-14 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| NeuroEPO plus (NeuralCIM®) in mild-to-moderate Alzheimer's clinical syndrome: the ATHENEA randomized clinical trial.Alzheimers Res Ther | PMID 38093366PMC10716956 | 2023-Dec-13 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Randomized, Double-Blind, Active Control, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Liztox® versus Botox® in Post-Stroke Upper Limb Spasticity.Toxins (Basel) | PMID 38133201PMC10748261 | 2023-Dec-12 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Randomized Placebo-Controlled Trial of the Anti-Nerve Growth Factor Antibody Tanezumab in Subjects With Cancer Pain Due to Bone Metastasis.Oncologist | PMID 37343145PMC10712717 | 2023-Dec-11 | 0.95 | The study is a Phase III randomized controlled trial in oncology patients with a drug intervention (tanezumab) and presents original results. However, the primary efficacy endpoint is change in pain score (continuous outcome) at week 8, not a time-to-event endpoint such as OS, PFS, DFS, EFS, RFS, TTP, or any Kaplan-Meier or hazard ratio analysis. Therefore, it does not meet the time-to-event criterion for inclusion in the KM digitization cohort. | 待处理 |
| Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer.J Clin Oncol | PMID 37669480无 PMCID | 2023-Dec-10 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer.J Clin Oncol | PMID 37695982PMC10713140 | 2023-Dec-10 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial.Lancet | PMID 37871604无 PMCID | 2023-Dec-09 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Efficacy and safety of CKD-495 in acute and chronic gastritis: A Phase III superiority clinical trial.Medicine (Baltimore) | PMID 38065906PMC10713194 | 2023-Dec-08 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes.N Engl J Med | PMID 37861217无 PMCID | 2023-Dec-07 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C.N Engl J Med | PMID 37870968无 PMCID | 2023-Dec-07 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| A phase 3 study evaluating the lot consistency, immunogenicity, safety, and tolerability of a Clostridioides difficile vaccine in healthy adults 65 to 85 years of age.Vaccine | PMID 37977942无 PMCID | 2023-Dec-07 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.N Engl J Med | PMID 38055253无 PMCID | 2023-Dec-07 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial.JAMA | PMID 38051328PMC10698618 | 2023-Dec-05 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| A randomized double-blind clinical trial on safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS): the statistical analysis plan of TUDCA-ALS trial.Trials | PMID 38053196PMC10696667 | 2023-Dec-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trial.Int J Gynecol Cancer | PMID 37935524无 PMCID | 2023-Dec-04 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.Lancet | PMID 37931634无 PMCID | 2023-Dec-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Perinatal Outcomes Associated With Management of Stage 1 Hypertension.Obstet Gynecol | PMID 37769314PMC10840706 | 2023-Dec-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cost-effectiveness analysis of an orphan drug tebentafusp in patients with metastatic uveal melanoma and a call for value-based pricing.Melanoma Res | PMID 37650713无 PMCID | 2023-Dec-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Five-Year Overall Survival Analysis of the JIPANG Study: Pemetrexed or Vinorelbine Plus Cisplatin for Resected Stage II-IIIA Nonsquamous Non-Small-Cell Lung Cancer.J Clin Oncol | PMID 37656928无 PMCID | 2023-Dec-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Neoadjuvant docetaxel, oxaliplatin plus capecitabine versus oxaliplatin plus capecitabine for patients with locally advanced gastric adenocarcinoma: long-term results of a phase III randomized controlled trial.Int J Surg | PMID 37678277PMC10720837 | 2023-Dec-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Comparison of 18F-PSMA-1007 and 18F-Choline PET/CT in prostate cancer patients with biochemical recurrence: a phase 3, prospective, multicenter, randomized study.Nucl Med Commun | PMID 37779440无 PMCID | 2023-Dec-01 | 0.95 | The study is a randomized, phase 3 trial in oncology with original results. However, it compares two diagnostic imaging agents (radiotracers) and evaluates diagnostic performance (detection rate, sensitivity), not a therapeutic drug intervention. Furthermore, it does not report a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). | 待处理 |
| Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial.JAMA Oncol | PMID 37796513PMC10557031 | 2023-Dec-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Combination of aspirin and rosuvastatin for reduction of venous thromboembolism in severely injured patients: a double-blind, placebo-controlled, pragmatic randomized phase II clinical trial (The STAT Trial).Blood Coagul Fibrinolysis | PMID 37942744PMC10655842 | 2023-Dec-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Brolucizumab for Diabetic Macular Edema: The KINGFISHER Randomized Clinical Trial.JAMA Ophthalmol | PMID 37971723PMC12512174 | 2023-Dec-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Clinically meaningful improvements in cutaneous lesions and quality of life measures in patients with atopic dermatitis with greater pruritus reductions after treatment with 60 mg nemolizumab subcutaneously every 4 weeks: subgroup analysis from a phase 3, randomized, controlled trial.J Dermatolog Treat | PMID 36779675无 PMCID | 2023-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |